Enlivex (ENLV) Short term Debt (2017 - 2019)
Enlivex (ENLV) posted quarterly Short term Debt of $14000.0 for Q3 2019, down 39.13% year-over-year from $23000.0 in Q3 2018, and little changed quarter-over-quarter from $14000.0 in Q2 2019.
Enlivex (ENLV) Short term Debt (2017 - 2019) Analysis & Trends
Enlivex's Short term Debt history runs 3 years deep, the most recent figure standing at $14000.0 for Q3 2019.
- In Q3 2019, Short term Debt fell 39.13% year-over-year to $14000.0; the TTM figure through Sep 2019 stood at $14000.0 (down 39.13% YoY), while the FY2018 annual figure was $78000.0, up 56.0% from the prior year.
- Short term Debt for Q3 2019 stood at $14000.0, roughly flat from $14000.0 in the prior quarter.
- The five-year high for Short term Debt was $78000.0 in Q4 2018, with the low at $14000.0 in Q1 2019.
- The 3-year median for Short term Debt is $18500.0 (2018), against an average of $32166.7.
- The sharpest annual moves came in 2018 and 2019: Short term Debt soared 56.0% in 2018, then plunged 39.13% in 2019.
- Enlivex's Short term Debt stood at $50000.0 in 2017, then jumped by 56.0% to $78000.0 in 2018, then slumped by 82.05% to $14000.0 in 2019.
- Business Quant data shows ENLV's Short term Debt at $14000.0 in Q3 2019, $14000.0 in Q2 2019, and $14000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 14,000.00 |
| Jun 30, 2019 | 14,000.00 |
| Mar 31, 2019 | 14,000.00 |
| Dec 31, 2018 | 78,000.00 |
| Sep 30, 2018 | 23,000.00 |
| Dec 31, 2017 | 50,000.00 |